Cardiomyopathy Review: 2023 ESC Guidelines & AHA/ACC Classification and Management

Abstract

Cardiomyopathies are a heterogeneous group of disorders associated with structural and functional abnormalities of the myocardium, leading to potentially life-threatening arrhythmias, heart failure, or sudden cardiac death.

This review synthesizes the comprehensive 2023 European Society of Cardiology (ESC) Guidelines for the Management of Cardiomyopathies and current American Heart Association/American College of Cardiology (AHA/ACC) recommendations. It covers the classification, diagnosis, and management of the primary morpho-functional types: Dilated (DCM), Hypertrophic (HCM), and Restrictive (RCM), along with the increasingly recognized Takotsubo syndrome (TTS).

Key updates integrated from the 2023 ESC document include refined diagnostic criteria, standardized genetic testing strategies, and the definitive incorporation of novel therapies like mavacamten for HCM and tafamidis for cardiac amyloidosis. These guidelines establish a framework for precise phenotyping and personalized, evidence-based care.

Introduction and Contemporary Classification

Cardiomyopathies, defined as diseases primarily affecting the heart muscle, represent a significant cause of global cardiovascular morbidity and mortality. They are traditionally classified by morpho-functional features—Dilated (DCM), Hypertrophic (HCM), and Restrictive (RCM)—but contemporary practice emphasizes integrating the etiological (underlying cause) and genetic basis for precise patient management.

Current clinical practice is primarily governed by the comprehensive 2023 ESC Guidelines for the Management of Cardiomyopathies and the specialized 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. These documents advocate for a multidisciplinary approach, ensuring patients receive robust risk stratification, advanced cardiac imaging (e.g., Cardiovascular Magnetic Resonance (CMR)), and tailored Guideline-Directed Medical Therapy (GDMT).

The core objectives of these updated standards are to:

1. Standardize Etiologic Workup: Promote genetic testing and family screening, particularly for DCM and HCM.
   
   
2. Refine Therapy: Integrate new, disease-modifying agents such as mavacamten for obstructive HCM and tafamidis for transthyretin cardiac amyloidosis.
   
   
3. Improve Outcomes: Provide clear guidance on sudden cardiac death (SCD) risk assessment and device therapy timing.
   
   

This review consolidates the latest criteria and management strategies from these governing bodies, focusing on the core phenotypes and the emerging role of targeted pharmacological therapies.

The ESC/AHA/ACC Classification System (Morpho-Functional and Etiological)

The integrated classification system promotes a comprehensive diagnostic workup that moves beyond structural assessment to include advanced imaging, genetic testing, and endomyocardial biopsy.

This review focuses on the most prevalent and clinically relevant phenotypes: DCM, HCM, RCM, and TTS, outlining the key diagnostic steps and management protocols consistent with current Class I evidence.

Dilated Cardiomyopathy (DCM)

Dilated Cardiomyopathy (DCM) is the most common form of primary cardiomyopathy, characterized by left ventricular (LV) or biventricular dilation and impaired systolic function (HFrEF), in the absence of abnormal loading conditions sufficient to cause the observed degree of dysfunction.

Etiology and Pathophysiology: Genetic vs. Non-Genetic Causes

Up to 40–50% of idiopathic cases have a genetic basis. The most frequently identified mutations occur in the gene encoding Titin (TTN). 

Other significant genes include those encoding Lamin A/C (LMNA), which often predispose to high-degree atrioventricular block. 

Non-genetic causes include myocarditis, toxic exposure, and Peripartum cardiomyopathy (PPCM). The pathological hallmark involves myocardial remodeling with interstitial fibrosis and myocyte loss, leading to progressive pump failure.

Guideline-Directed Medical Therapy (GDMT) for HFrEF in DCM

The management of DCM centers on the optimization of GDMT for Heart Failure with Reduced Ejection Fraction (HFrEF), consistent with Class I recommendations.

Practice Highlight: Four Pillars of GDMT Current guidelines emphasize the rapid initiation and titration of all four pharmacologic classes (ARNI/ACEi, Beta-Blocker, MRA, SGLT2i) to target doses to maximize clinical benefit.

Role of Advanced Therapies (Device and Transplant)

• Implantable Cardioverter-Defibrillator (ICD): Recommended for primary prevention in patients with DCM who remain symptomatic (NYHA Class II or III) despite optimal GDMT for ≥ 3 months, and who have an ejection fraction (LVEF) ≤35%.
  
  
• Cardiac Resynchronization Therapy (CRT): Indicated for HFrEF patients with LVEF ≤ 35%, NYHA ≥ II symptoms, and a wide QRS complex (≥ 150 ms) with Left Bundle Branch Block (LBBB) morphology.
  
  
• Cardiac Transplantation remains the definitive treatment for end-stage DCM refractory to maximal GDMT.
  
  

Hypertrophic Cardiomyopathy (HCM)

Hypertrophic Cardiomyopathy (HCM) is an autosomal dominant genetic disorder defined by unexplained left ventricular (LV) hypertrophy—typically ≥ 15 mm wall thickness—that is not accounted for solely by abnormal loading conditions.

Genetic Basis and Sarcomeric Mutations

The majority of HCM cases are caused by mutations in genes encoding sarcomeric proteins, most frequently the beta-myosin heavy chain (MYH7) and the myosin-binding protein C (MYBPC3). These mutations lead to hypercontractility and impaired diastolic function. 

Left Ventricular Outflow Tract (LVOT) Obstruction occurs in about two-thirds of patients due to systolic anterior motion (SAM) of the mitral valve apparatus.

Diagnosis: Multimodality Imaging and LVOT Obstruction

Echocardiography defines the extent of hypertrophy and assesses the presence and severity of dynamic LVOT obstruction (gradient ≥ 30 mmHg). 

Cardiac Magnetic Resonance (CMR) is crucial for tissue characterization, identifying late gadolinium enhancement (LGE), a predictor of sudden cardiac death (SCD) risk.

Risk Stratification for Sudden Cardiac Death (SCD)

The ESC HCM Risk-SCD Calculator provides an individualized 5-year risk score to guide ICD implantation decisions for primary prevention. Key risk factors include prior cardiac arrest, massive LV hypertrophy (≥ 30 mm), family history of SCD, unexplained syncope, and extensive LGE on CMR.

Management of Obstructive HCM: Mavacamten, Septal Reduction Therapy

• Pharmacologic Therapy (First Line): Beta-blockers and non-dihydropyridine calcium channel blockers reduce contractility and the LVOT gradient.
  
  
• Sarcomere-Targeted Therapy: Mavacamten, a selective cardiac myosin inhibitor, lowers contractility and demonstrably reduces the LVOT gradient, improving symptoms in obstructive HCM patients, supported by the EXPLORER-HCM trial.
  
  
• Septal Reduction Therapy (SRT): For severe, persistent symptoms refractory to maximal medical therapy, Surgical Septal Myectomy (gold standard) or Alcohol Septal Ablation are indicated.
  
  

Practice Highlight: Novel Therapies in HCM The introduction of Mavacamten, the first selective cardiac myosin inhibitor, targets the fundamental hypercontractile mechanism of the disease and is a major therapeutic advance.

Restrictive Cardiomyopathy (RCM)

Restrictive Cardiomyopathy (RCM) is characterized by impaired ventricular filling (severe diastolic dysfunction) due to excessively stiff, non-compliant ventricular walls, despite preserved systolic function initially.

Differential Diagnosis: Infiltrative vs. Storage Disorders

The etiology dictates treatment. The most common form is Cardiac Amyloidosis (AL and ATTR types). Other causes include Sarcoidosis (infiltrative) and Hemochromatosis (storage). Distinguishing RCM from constrictive pericarditis is essential.

Diagnostic Utility of Cardiac Magnetic Resonance (CMR) and Biopsy

• Echocardiography: Reveals severe bi-atrial enlargement and restrictive filling patterns.
  
  
• CMR: Highly sensitive for characterizing tissue. LGE, particularly in a global subendocardial pattern, is highly suggestive of amyloidosis.
  
  
• Endomyocardial Biopsy (EMB): Remains the gold standard for definitive histological confirmation.
  
  
• Non-Invasive Amyloid Staging: Tc-PYP scintigraphy is Class I evidence for diagnosing ATTR-amyloidosis in the absence of a monoclonal gammopathy.
  
  

Targeted Therapy for Cardiac Amyloidosis (ATTR and AL)

Management focuses on disease-specific interventions:

• ATTR Amyloidosis: Treatment involves stabilizing the TTR tetramer or silencing its production. Tafamidis (TTR stabilizer) significantly reduces cardiovascular-related hospitalization and mortality, supported by the ATTR-ACT trial.
  
  
• AL Amyloidosis: Management is oncologic, focused on treating the underlying plasma cell dyscrasia using chemotherapy regimens or stem cell transplantation.
  
  

Practice Highlight: The Importance of Etiology. The prognosis and treatment of RCM are almost entirely dictated by the etiology. Early diagnosis and targeted intervention for cardiac amyloidosis are critical, as standard GDMT is often poorly tolerated.

Takotsubo Syndrome (TTS)

Takotsubo Syndrome (TTS) is a non-ischemic cardiomyopathy characterized by transient regional wall motion abnormalities of the left ventricle, typically with apical ballooning, following a severe physical or emotional stressor.

Clinical Presentation and Differentiation from Acute Coronary Syndrome (ACS)

Patients present with symptoms mimicking an Acute Coronary Syndrome (ACS) (chest pain, dyspnea), often with ST-segment elevation on ECG. Cardiac troponins are elevated but lower relative to the extent of wall motion abnormality. Coronary Angiography reveals no significant obstructive coronary artery disease. Diagnosis is guided by the InterTAK Diagnostic Criteria.

Proposed Pathophysiology: Catecholamine Excess and Microvascular Dysfunction

The primary proposed mechanism is an excessive sympathetic stimulation and catecholamine release. The massive surge of catecholamines is hypothesized to induce direct myocyte injury and microvascular dysfunction, leading to transient myocardial stunning.

Management and Long-Term Prognosis

Management of the acute phase is largely supportive.

• Acute Phase: Beta-blockers are used for patients with LVOT obstruction. Therapeutic anticoagulation is often recommended due to the high risk of left ventricular thrombus (LVT) formation until wall motion normalizes.
  
  
• Long-Term Management: TTS is generally reversible. Long-term use of beta-blockers and ACE inhibitors/ARBs is generally recommended until functional recovery is confirmed.
  
  

Special Populations and Emerging Research

Cardiomyopathy in Pediatric and Peripartum Settings

• Pediatric Cardiomyopathy: Often genetically driven. Early genetic testing is crucial for guiding risk stratification and family counseling. The threshold for advanced support (VADs, heart transplantation) is often lower.
  
  
• Peripartum Cardiomyopathy (PPCM): Linked to cardiotoxic prolactin fragments. Management involves standard HFrEF GDMT (avoiding ACEi/ARBs in pregnancy) and emerging therapies like Bromocriptine to inhibit prolactin release.
  
  

Genetic Counseling and Cascade Screening

Cascade screening of first-degree relatives with targeted genetic counseling and phenotypic screening (ECG, echo) is mandatory following the identification of a pathogenic mutation (proband). This allows for early, preventive interventions.

Emerging Therapies and Research Directions

The field is rapidly advancing towards precision medicine:

1. Gene Therapy and Gene Editing: Research is focusing on in vivo gene correction for monogenic cardiomyopathies (MYBPC3, TTN).
   
   
2. Anti-Amyloid Agents: Continued development of agents targeting amyloid fibril clearance and formation beyond current stabilizers.
   
   
3. Myocarditis and Immunomodulation: Trials are investigating the role of immunosuppressive agents in patients with biopsy-proven chronic active myocarditis to potentially halt disease progression.
   
   

Practice Highlight: The Genetic Revolution Routine access to genetic testing and its integration with clinical care (cascade screening) is transforming the early identification and pre-symptomatic management of inheritable cardiomyopathies.

Clinical Practice Summary and Key Takeaways

Optimal care requires a shift toward etiology-specific diagnosis and genetic risk stratification. Precise phenotyping, supported by multimodality imaging and genetic testing, is foundational for improving long-term outcomes.

Multidisciplinary Team Approach

Optimal care necessitates collaboration across Heart Failure Specialists, Electrophysiologists, Advanced Imaging Specialists, and Genetic Counselors.